IP Library Granted Patent US 8,071,315
Granted Patent B2
US 8,071,315 · App. 12/433,481 · Granted Dec 6, 2011

Detecting Bcl-B expression in cancer and uses thereof

Assignee: Sanford-Burnham Medical Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,315
App. No.
12/433,481
Granted
Dec 6, 2011
Kind
B2
Abstract

Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer.

Claims (9)

1. A method of selecting a therapy for treating a subject with breast cancer or prostate cancer, comprising examining the expression of Bcl-B in one or more cells of said cancer, wherein a higher amount of Bcl-B expression in the cancer cells or a higher number or percentage of cancer cells with detectable Bcl-B expression as compared to that of non-metastatic reference cells indicates that the selected treatment is adjuvant chemotherapy or hormonal therapy, wherein a lower or equivalent amount of Bcl-B expression in the cancer cells or a lower or equivalent number or percentage of cancer cells with detectable Bcl-B expression as compared to that of non-metastatic reference cells indicates that the selected treatment is surgery, local therapy, or a combination thereof.

2. The method of claim 1 , wherein the reference cells comprise healthy cells from the same tissue of the subject as the cancer cells.

3. The method of claim 1 , wherein the reference cells comprise non-cancerous cells of same tissue from the subject.

4. The method of claim 1 , wherein the reference cells comprise non-cancerous cells of same tissue from one or more unrelated individuals.

5. The method of claim 1 , wherein the reference cells comprise non-cancerous cells from the same tissue of the subject as the cancer cells.

6. A method of selecting a therapy for treating a subject with lung cancer, comprising examining the expression of Bcl-B in one or more cells of said cancer, wherein a higher amount of Bcl-B expression in the cancer cells or a higher number or percentage of cancer cells with detectable Bcl-B expression as compared to that of non-metastatic reference cells indicates that the selected treatment is aggressive chemotherapy, investigational drugs, or a combination thereof.

7. The method of claim 6 , wherein the reference cells comprise healthy cells from the same tissue of the subject as the cancer cells.

8. The method of claim 6 , wherein the reference cells comprise non-cancerous cells of same tissue from the subject.

9. The method of claim 6 , wherein the reference cells comprise non-cancerous cells of same tissue from one or more unrelated individuals.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 21, 2022
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 060575/0294 →
CHANGE OF NAME Recorded Dec 3, 2010
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 025442/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2009
From: REED, JOHN C.; KRAJEWSKA, MARYLA
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 023093/0455 →
Continuity (2)
Provisional Application 61048995 · Apr 30, 2008
Related Publication 20090275040A1 · Nov 5, 2009